Following evidence demonstrating the superiority of tyrosine kinase inhibitors (TKIs) over chemotherapy for advanced NSCLC with epidermal growth factor receptor (EGFR) mutations, the treatment landscape has rapidly advanced with the introduction of newer EGFR TKIs, such as Osimertinib [2,3,4]. Here, EGFR is linked to non-small cell lung carcinoma.